- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03051425
Immune Benefits of Consumption of Dairy Yogurt in Elderly
February 9, 2017 updated by: Yonsei University
Immune Benefits of Consumption of Dairy Yogurt Containing Functional Probiotics Among Individuals Over 60 Years Old
To investigate the impact of consuming dairy yogurt on immun function including natural killer (NK) cell activity, circulating levels of cytokines, and immunoglobulin (Ig) in elderly.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A randomized, open-labelled, placebo-controlled study was conducted on 200 nondiabetic, nonobese and elderly (≥60 years) subjects.
Over a twelve-week period, the test group consumed one bottle (120 mL) of dairy yogurt each day, whereas the placebo group consumed same volume of low fat milk daily.
NK cell activity (%) was measured based on the ratios of effector cells (E; peripheral blood mononuclear cells, PBMCs) from each participant to target cells (T; K562 cells) at E:T= 10:1, 5:1, 2.5:1, 1.25:1 or 0.625:1.
In addition, cytokines and immunoglobulin levels measured using commercial kits as manufacturer's instruction.
Study Type
Interventional
Enrollment (Actual)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 03722
- Yonsei University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to give informed consent
- Over 60 years old without any health problems
- The levels of white blood cells within range 4x10^3/μL~10x10^3/μL
Exclusion Criteria:
- Individuals who get a cold
- Diabetes
- Hypersensitivity or disease history for milk protein
- Epilepsy, neurological, or psychological disease
- Alcoholism or drug addiction
- Liver disease or severe kidney failure disease
- Inflammation-related disease
- Consumption of other test products or drugs within 1 month prior to screening
- Regular consumption of immune-related functional foods including yogurt or milk within 1 month prior to screening
- History of inflammation-related disease or taking medication to treat inflammation-related disease within 1 month prior to screening
- History of cancer within 5 years
- Any inappropriate condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo group
Placebo supplementation
|
120 mL of low-fat milk
|
|
Experimental: Test group
Probiotic yogurt supplementation
|
120 mL of Yogurt containing Lactobacillus delbrueckii subsp.
bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp.
lactis, and Lactobacillus plantarum
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Natural killer cell activity
Time Frame: At baseline
|
At baseline
|
|
Natural killer cell activity
Time Frame: At 12-week follow-up
|
At 12-week follow-up
|
|
Change from baseline natural killer cell activity at 12-week
Time Frame: At baseline and 12-week follow-up
|
At baseline and 12-week follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
White blood cell
Time Frame: At baseline
|
At baseline
|
|
Interleukin-12
Time Frame: At baseline
|
At baseline
|
|
Interferon-gamma
Time Frame: At baseline
|
At baseline
|
|
White blood cell
Time Frame: At 12-week follow-up
|
At 12-week follow-up
|
|
Change from baseline white blood cell at 12-week
Time Frame: At baseline and 12-week follow-up
|
At baseline and 12-week follow-up
|
|
Interleukin-12
Time Frame: At 12-week follow-up
|
At 12-week follow-up
|
|
Change from baseline Interleukin-12 at 12-week
Time Frame: At baseline and 12-week follow-up
|
At baseline and 12-week follow-up
|
|
Interferon-gamma
Time Frame: At 12-week follow-up
|
At 12-week follow-up
|
|
Change from baseline Interferon-gamma at 12-week
Time Frame: At baseline and 12-week follow-up
|
At baseline and 12-week follow-up
|
|
Immunoglobulin
Time Frame: At baseline
|
At baseline
|
|
Immunoglobulin
Time Frame: At 12-week follow-up
|
At 12-week follow-up
|
|
Change from baseline immunoglobulin at 12-week
Time Frame: At baseline and 12-week follow-up
|
At baseline and 12-week follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jong Ho Lee, Yonsei University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2016
Primary Completion (Actual)
January 10, 2017
Study Completion (Actual)
February 8, 2017
Study Registration Dates
First Submitted
February 9, 2017
First Submitted That Met QC Criteria
February 9, 2017
First Posted (Actual)
February 13, 2017
Study Record Updates
Last Update Posted (Actual)
February 13, 2017
Last Update Submitted That Met QC Criteria
February 9, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CI_immune
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.